You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR1-3 Rearrangements

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Rearrangements
  • Albuquerque, New Mexico
  • +100 more
Feb 1, 2023

AML, Adult Trial (Biological characterization of AML with MECOM or atypical 3q26 rearrangements)

Not yet recruiting
  • AML, Adult
  • Biological characterization of AML with MECOM or atypical 3q26 rearrangements
  • (no location specified)
Apr 21, 2023

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Tumors (MLN)

Active, not recruiting
  • Advanced or Metastatic Solid Tumor
  • +2 more
  • Gilbert, Arizona
  • +60 more
Oct 20, 2022

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

NSCLC (NSCLC) Trial in Worldwide (Pemigatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Los Angeles, California
  • +41 more
Jun 27, 2022

Glioblastoma, Adult-type Diffuse Gliomas Trial in Worldwide (Pemigatinib)

Recruiting
  • Glioblastoma
  • Adult-type Diffuse Gliomas
  • Beverly Hills, California
  • +83 more
Jul 25, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (TPX-0005, Metformin Hydrochloride, Digoxin)

Recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Canton, Ohio
    Gabrail Cancer Research Center
Apr 25, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • (no location specified)
Feb 3, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Advanced Intrahepatic Cholangiocarcinoma Trial (Pemigatinib)

Not yet recruiting
  • Advanced Intrahepatic Cholangiocarcinoma
  • (no location specified)
Sep 30, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Breast Cancer Metastatic, Hormone Receptor Positive Malignant Tumor of Breast Trial in Spain (Combination, Rogaratinib +

Recruiting
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Combination, Rogaratinib + palbociclib + fulvestrant
  • Hospitalet de Llobregat, Barcelona, Spain
  • +7 more
Feb 8, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022